Completed PHASE2 INTERVENTIONAL NCT00068276

Cholecalciferol in Treating Patients With Myelodysplastic Syndrome

Orthomolecular Vitamin D3 in Low-Risk Myelodysplastic Syndrome: An Open-Label Clinical Trial

Sponsor: National Cancer Institute (NCI)

Conditions Leukemia Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Neoplasms

Updated 6 times since 2017 Last updated: Aug 8, 2018 Started: Jul 31, 2003 Primary completion: Jun 30, 2005 Completion: Sep 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00068276, this PHASE2 trial focuses on Leukemia and Myelodysplastic Syndromes and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 6 times since 2003, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Sep 2018 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Sep 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jul 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)
Wake Forest University Health Sciences

Data source: Wake Forest University Health Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Winston-Salem, United States